A role for Nucleocapsid-specific antibody function in Covid-19 Convalescent plasma therapy
Summary COVID-19 convalescent plasma (CCP), a passive polyclonal antibody therapeutic, has exhibited mixed results in the treatment of COVID-19. Given that the therapeutic effect of CCP may extend beyond the ability of SARS-CoV-2-specific antibody binding and neutralization to influence the evolution of the endogenous antibody response, we took a systematic and comprehensive approach to analyze SARS-CoV-2 functional antibody profiles of participants in a randomized controlled trial of CCP treatment of individuals hospitalized with COVID-19 pneumonia where CCP was associated with both decreased mortality and improved clinical severity. Using systems serology, we found that the clinical benefit of CCP is related to a shift towards reduced inflammatory Spike (S) responses and enhanced Nucleocapsid (N) humoral responses. We found CCP had the greatest clinical benefit in participants with low pre-existing anti-SARS-CoV-2 antibody function, rather than S or N antibody levels or participant demographic features. Further, CCP induced immunomodulatory changes to recipient humoral profiles persisted for at least two months, marked by the selective evolution of anti-inflammatory Fc-glycan profiles and persistently expanded nucleocapsid-specific humoral immunity following CCP therapy. Together, our findings identify a novel mechanism of action of CCP, suggest optimal patient characteristics for CCP treatment, identify long-last immunomodulatory effects of CCP, and provide guidance for development of novel N-focused antibody therapeutics for severe COVID-19 hyperinflammation..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
bioRxiv.org - (2022) vom: 25. Feb. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Herman, Jonathan D. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2022.02.19.22271230 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI035316373 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI035316373 | ||
| 003 | DE-627 | ||
| 005 | 20230429080247.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220224s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.02.19.22271230 |2 doi | |
| 035 | |a (DE-627)XBI035316373 | ||
| 035 | |a (biorXiv)10.1101/2022.02.19.22271230 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Herman, Jonathan D. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A role for Nucleocapsid-specific antibody function in Covid-19 Convalescent plasma therapy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Summary COVID-19 convalescent plasma (CCP), a passive polyclonal antibody therapeutic, has exhibited mixed results in the treatment of COVID-19. Given that the therapeutic effect of CCP may extend beyond the ability of SARS-CoV-2-specific antibody binding and neutralization to influence the evolution of the endogenous antibody response, we took a systematic and comprehensive approach to analyze SARS-CoV-2 functional antibody profiles of participants in a randomized controlled trial of CCP treatment of individuals hospitalized with COVID-19 pneumonia where CCP was associated with both decreased mortality and improved clinical severity. Using systems serology, we found that the clinical benefit of CCP is related to a shift towards reduced inflammatory Spike (S) responses and enhanced Nucleocapsid (N) humoral responses. We found CCP had the greatest clinical benefit in participants with low pre-existing anti-SARS-CoV-2 antibody function, rather than S or N antibody levels or participant demographic features. Further, CCP induced immunomodulatory changes to recipient humoral profiles persisted for at least two months, marked by the selective evolution of anti-inflammatory Fc-glycan profiles and persistently expanded nucleocapsid-specific humoral immunity following CCP therapy. Together, our findings identify a novel mechanism of action of CCP, suggest optimal patient characteristics for CCP treatment, identify long-last immunomodulatory effects of CCP, and provide guidance for development of novel N-focused antibody therapeutics for severe COVID-19 hyperinflammation. | ||
| 700 | 1 | |a Wang, Chuangqi |e verfasserin |4 aut | |
| 700 | 1 | |a Burke, John Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Zur, Yonatan |e verfasserin |4 aut | |
| 700 | 1 | |a Compere, Hacheming |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Jaewon |e verfasserin |4 aut | |
| 700 | 1 | |a Macvicar, Ryan |e verfasserin |4 aut | |
| 700 | 1 | |a Shin, Sally |e verfasserin |4 aut | |
| 700 | 1 | |a Frank, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Siegel, Don |e verfasserin |4 aut | |
| 700 | 1 | |a Tebas, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Grace H. |e verfasserin |4 aut | |
| 700 | 1 | |a Shaw, Pamela A. |e verfasserin |4 aut | |
| 700 | 1 | |a Yoon, Hyunah |e verfasserin |4 aut | |
| 700 | 1 | |a Pirofski, Liise-anne |e verfasserin |4 aut | |
| 700 | 1 | |a Juelg, Boris |e verfasserin |4 aut | |
| 700 | 1 | |a Bar, Katharine J. |e verfasserin |4 aut | |
| 700 | 1 | |a Lauffenburger, Douglas |e verfasserin |4 aut | |
| 700 | 1 | |a Alter, Galit |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2022) vom: 25. Feb. |
| 773 | 1 | 8 | |g year:2022 |g day:25 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.02.19.22271230 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 25 |c 02 | ||
| 953 | |2 045F |a 570 | ||